LG Life Science LTD. – Product Pipeline Review

Global Markets Direct’s, ‘LG Life Science LTD. – Product Pipeline Review – 2016’, provides an overview of the LG Life Science LTD.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by LG Life Science LTD., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of LG Life Science LTD.

The report provides overview of LG Life Science LTD. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses LG Life Science LTD.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features LG Life Science LTD.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate LG Life Science LTD.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for LG Life Science LTD.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding LG Life Science LTD.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

LG Life Science LTD. Snapshot 7

LG Life Science LTD. Overview 7

Key Facts 7

LG Life Science LTD. - Research and Development Overview 8

Key Therapeutic Areas 8

LG Life Science LTD. - Pipeline Review 12

Pipeline Products by Stage of Development 12

Pipeline Products - Monotherapy 13

Pipeline Products - Combination Treatment Modalities 14

Pipeline Products - Partnered Products 15

Partnered Products/Combination Treatment Modalities 16

Pipeline Products - Out-Licensed Products 17

Out-Licensed Products/Combination Treatment Modalities 18

LG Life Science LTD. - Pipeline Products Glance 19

LG Life Science LTD. - Late Stage Pipeline Products 19

Pre-Registration Products/Combination Treatment Modalities 19

Phase III Products/Combination Treatment Modalities 20

LG Life Science LTD. - Clinical Stage Pipeline Products 21

Phase II Products/Combination Treatment Modalities 21

Phase I Products/Combination Treatment Modalities 22

LG Life Science LTD. - Early Stage Pipeline Products 23

Preclinical Products/Combination Treatment Modalities 23

Discovery Products/Combination Treatment Modalities 24

LG Life Science LTD. - Unknown Stage Pipeline Products 25

Unknown Products/Combination Treatment Modalities 25

LG Life Science LTD. - Drug Profiles 26

(gemigliptin + glimepiride) - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

(gemigliptin + metformin hydrochloride) - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

(gemigliptin + rosuvastatin calcium) - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

(lercanidipine hydrochloride + valsartan) - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

adalimumab biosimilar - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

etanercept biosimilar - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Eupenta - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

exenatide SR - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

infliximab biosimilar - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

interferon alfa-2a SR - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

LBDE - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

LBVC - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

LBVD - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

LBVE-013 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

LBVE-014 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

LC-231306 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

LC-280126 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

LC-280391 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

LC-34AD3 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

LC-350189 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

LC-541239 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

LC-65AOD3 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

LD-02GIFRO - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Monoclonal Antibody to Inhibit VEGF for Cancer - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

NecX - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

nivocasan - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

rituximab biosimilar - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Small Molecule to Inhibit PAR-1 for Atherothrombosis - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Small Molecules for Obesity - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecules to Inhibit 20S Proteasome for Multiple Myeloma and Solid Tumor - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

somatropin - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

somatropin SR - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

LG Life Science LTD. - Pipeline Analysis 59

LG Life Science LTD. - Pipeline Products by Target 59

LG Life Science LTD. - Pipeline Products by Route of Administration 62

LG Life Science LTD. - Pipeline Products by Molecule Type 63

LG Life Science LTD. - Pipeline Products by Mechanism of Action 64

LG Life Science LTD. - Dormant Projects 67

LG Life Science LTD. - Locations And Subsidiaries 68

Head Office 68

Other Locations & Subsidiaries 68

Appendix 70

Methodology 70

Coverage 70

Secondary Research 70

Primary Research 70

Expert Panel Validation 70

Contact Us 70

Disclaimer 71

List of Tables

List of Tables

LG Life Science LTD., Key Facts 7

LG Life Science LTD. – Pipeline by Indication, 2016 10

LG Life Science LTD. – Pipeline by Stage of Development, 2016 12

LG Life Science LTD. – Monotherapy Products in Pipeline, 2016 13

LG Life Science LTD. – Combination Treatment Modalities in Pipeline, 2016 14

LG Life Science LTD. – Partnered Products in Pipeline, 2016 15

LG Life Science LTD. – Partnered Products/ Combination Treatment Modalities, 2016 16

LG Life Science LTD. – Out-Licensed Products in Pipeline, 2016 17

LG Life Science LTD. – Out-Licensed Products/ Combination Treatment Modalities, 2016 18

LG Life Science LTD. – Pre-Registration, 2016 19

LG Life Science LTD. – Phase III, 2016 20

LG Life Science LTD. – Phase II, 2016 21

LG Life Science LTD. – Phase I, 2016 22

LG Life Science LTD. – Preclinical, 2016 23

LG Life Science LTD. – Discovery, 2016 24

LG Life Science LTD. – Unknown, 2016 25

LG Life Science LTD. – Pipeline by Target, 2016 60

LG Life Science LTD. – Pipeline by Route of Administration, 2016 62

LG Life Science LTD. – Pipeline by Molecule Type, 2016 63

LG Life Science LTD. – Pipeline Products by Mechanism of Action, 2016 65

LG Life Science LTD. – Dormant Developmental Projects,2016 67

LG Life Science LTD., Other Locations 68

LG Life Science LTD., Subsidiaries 69

List of Figures

List of Figures

LG Life Science LTD. – Pipeline by Top 10 Indication, 2016 9

LG Life Science LTD. – Pipeline by Stage of Development, 2016 12

LG Life Science LTD. – Monotherapy Products in Pipeline, 2016 13

LG Life Science LTD. – Combination Treatment Modalities in Pipeline, 2016 14

LG Life Science LTD. – Out-Licensed Products in Pipeline, 2016 17

LG Life Science LTD. – Pipeline by Top 10 Target, 2016 59

LG Life Science LTD. – Pipeline by Route of Administration, 2016 62

LG Life Science LTD. – Pipeline by Molecule Type, 2016 63

LG Life Science LTD. – Pipeline Products by Top 10 Mechanism of Action, 2016 64

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports